We study the time varying biodistribution of ferrite ͑Fe 3 O 4 ͒ nanoparticles upon in vivo injection. For this purpose, a novel process of directly labeling radioactive Tc-99m with ferrite nanoparticles was developed. The radiobeads serve as a tracer to provide information on the uptake of injected particles by organs. In the course of our study, Tc-99m labeled ferrite beads were intravenously injected into the tail vein of rats. The time course of changes in the radio-intensity of heart, lung, and liver could be achieved by real-time scintigraphic images. It was observed that the particle uptake by organs is very fast and completed within the first few minutes after intravenous injection. The pharmacokinetic behavior of the radiobead uptake was quantitatively described by a two-compartment model.
I. INTRODUCTION
Biocompatible iron oxide magnetic nanoparticles ͑MNPs͒ can be used in a wide variety of biomedical applications.
1-10 Magnetic separation is one of the practices that utilize the MNPs to label biological entities, such as DNA, proteins, and cells, for purification and enrichment. The magnetically labeled bioentities can then be advanced for magnetic detection in a lab-on-a-chip approach utilizing a giant magnetoresistance detector 10 or magnetoimpedance sensing, etc.
11,12
Another practical application is the use of MNPs as contrast agents for in vivo diagnosis in magnetic resonance imaging ͑MRI͒. 13 It has been demonstrated that the iron oxide MNPs notably enhance the image contrast and efficiently differentiate healthy and pathological tissues. The iron oxide nanoparticles, due to their low toxicity, have received U.S. Food and Drug Administration approval to be used as MRI signal enhancers. Progressive development has been done by using human-grade superparamagnetic iron oxide MNPs for magnetic resonance-based tracking of intravenously injected magnetically labeled stem cell and for monitoring of the distribution of transplanted stem cells in the body. 13 The MNPs have shown great therapeutic promise in utilization as a carrier to be conjugated with chemotherapeutic drugs and to target disease sites by external magnetic fields.
14 The magnetic control of cytotoxic drug release in cancer treatment takes the advantage of a highly localized drug concentration and diminishing side effects. This principle is also explored in radiotherapy, which utilizes MNPs labeled with radio-nuclides in order to enrich radioactivity at the desired location and consequently reduce damage to surrounding tissue. 9 To realize practical clinical applications, the knowledge of organ distribution and the final fate of the injected drug/carrier complex is necessary.
In our previous works, 15, 16 we have developed a novel approach to directly label the radioisotope technetium-99m ͑Tc-99m͒ with ferrite nanoparticles. The approach needs no chemical coating overlayer on the ferrite nanoparticles and therefore keeps the particle size small. As prepared, radiolabeled ferrite nanoparticles have shown high labeling efficiency for the half-life period of Tc-99m and are, accordingly, applicable to long term monitoring of the organ uptake of injected nanoparticles. Since the time resolution of dynamic scintigraphic images, detected by a gamma camera, can achieve several frames per second, the methodology is also able to investigate the initial stage time varying uptake and release of particles by the organ under study upon intravenous injection. In this article, we present the in vivo study of the pharmacokinetic behavior of intravenously injected ferrite nanoparticles labeled with Tc-99m, and we explore the initial stage uptake and translocation of nanoparticles by heart, lung, and liver.
II. EXPERIMENTS
The ferrite ͑Fe 3 O 4 ͒ nanoparticles used in this study were synthesized from a reaction solution of FeCl 2 ͑0.05M͒ and FeCl 3 ͑0.05M͒ and an adjusting solution of NH 4 OH ͑50 ml͒. The synthesis was done at room temperature, and the pH value of the aqueous solution was near neutral. 17 At the final stage, the black nanoparticles of Fe 3 O 4 were precipitated in the solution. X-ray diffraction characterization has shown a pattern typical of Fe 3 O 4 . The average diameter of a particle is around 10-25 nm, as deduced from an analysis of the x-ray diffraction peak by Langevin's formula. The dried powder of as prepared particles shows a nearly superpara- 
The radiotracer, Tc-99m with a radioactivity of 1.11 GBq ͑30 mCi͒, was prepared as routine process in nuclear medicine at a hospital facility. To label the ferrite nanoparticles with a radiotracer, the preprocessed Tc-99m was injected into a sterile vacuum collecting vial ͑5 ml in volume͒. Subsequently, a stannous solution ͑0.5 ml͒ served as a reducing agent, which reduced the surface charge of Tc-99m to a suitable condition for labeling. It was injected into the vial and stirred for 10 s. In the meanwhile, a diluted ferrite nanoparticle solution was prepared by extracting 0.1 ml solution containing the ferrite nanoparticles and diluting it with 0.9 ml pyrogen-free isotonic saline. Then, the diluted ferrite nanoparticle solution of 0.5 ml was added into the vial containing the Tc-99m. The resultant solution was kept at room temperature for 2 min in order to achieve an entire labeling of the radiotracer with ferrite nanoparticles.
The labeling efficiency of as prepared radiobeads was checked by an instant thin-layer chromatography method before each in vivo experiment. The radio-labeling efficiency was more than 90% initially and reduced to less than 5% within the first 50 min. The labeling efficiency was nearly unvarying in the half-life time of Tc99m.
III. RESULTS AND DISCUSSION
To explore the time evolution of in vivo biodistribution of nanobeads, the Tc-99m labeled ferrite nanoparticles were intravenously injected into the tail vein of Wistar rats ͑male, 200-250 g͒. The scintigraphic images were monitored by a planar type gamma camera ͑GE, DST XLi͒ with a parallel collimator. The radio-intensity of each organ was analyzed by a graphic tool from a selected area of the scintigraphic images and was normalized by that of the whole rat body. The scintigraphic images, obtained from the planar gamma camera, have been autorescaled to the brightest intensity of each scintigram by the equipment software. Thus, the radiointensity in a scintigraphic image is a relative result rather than an absolute value. In the course of this study, we have further normalized the radio-intensity by that of the whole body. Figure 1 demonstrates the time evolution of the normalized radio-intensity of the upper chest ͑attributed mainly to lung and heart uptake͒ and lower chest ͑mainly due to liver uptake͒ of a rat upon an in vivo ͑i.v.͒ injection of 12 nm ferrite particles labeled as Tc-99m radioisotope. As shown in Fig. 1 , the normalized radio-intensity of the upper chest increases rapidly, in approximately logarithmical function of time, upon the administration of intravenously injected ferrite radiobeads. After reaching a maximum, the radiointensity decreases in a slow slope as a function of time. On the other hand, the radio-intensity of the lower chest increases monotonically to a plateau after about 60 s. The radio-intensity of this plateau is far apart from the upper chest value after a long duration. Since the normalized radiointensity is related to the ratio of radiobead uptake by organs to that by the whole body, the observed time evolution of the radio-intensity is ascribed to the kinetic process of absorption and excretion of radiobeads by the organism.
Further, an analysis was carried out in order to tell apart the kinetic behavior of radiobead uptake by lung, heart, and liver. In the course of this analysis, the radio-intensity of a selected area was divided by the selected area and further normalized to that of the whole body, divided by the area of the whole body. We call this value the normalized radiodensity. Figure 2 displays the initial stage time variation of the normalized radio-density of lung, heart, and liver of rat upon i.v. injection of 12 nm ferrite radiobeads. As illustrated in Fig. 2 , there appear several characteristic features. ͑1͒ A characteristic feature of the heart is that the normalized radio-density rises rapidly within the first few seconds to a peak value, and after the peak the radio-intensity decreases slowly as a function of time. ͑2͒ A characteristic feature of the lung is that the normalized radio-density increases with increasing time, in approximately a logarithmical function. ͑3͒ A characteristic feature of the liver is that the normalized radio-density increases nonlinearly toward a low plateau. ͑4͒ Each of the normalized radio-density values for heart and lung approaches toward a common plateau after about 60 s, and the value of this plateau is far apart from that of the liver after a long duration. The observed time variation of the normalized radio-density of each organ is in correspondence to the pharmacokinetics of radiobead uptake by the organs.
The compartmental model has been well used to describe the pharmacokinetic process of absorption and excretion of substances upon administration. 18 To qualitatively describe the observed initial stage characteristic of the radiobead uptake, we have attempted to adapt a twocompartment model where one compartment represents the heart and the other the lung. The variation in radiobead concentration in the heart and lung is in accordance with the cardiac diastole and systole processes for perfusion and ejection of radiobeads in each organ. At the initial stage ͑from time zero͒ upon i.v. injection, the intravenous radiobead stream fills into the heart. After early rapid filling, the radiobead stream perfuses into the lung under an ejection process of ventricular systole. During the cardiac cycles, the radiobead flow was sequentially driven from the lung into the liver and then increased slowly toward a nearly constant retaining value in the long run.
The retaining concentration of radiobeads in organs strongly depends on the properties of beads, such as particle size and surface charge. As reported, the uptake of radiobeads is associated with the mononuclear phagocytic system ͑MPS͒. 16 To diminish the uptake by MPS, a surface modification of coating poly͑ethyelene glycol͒ ͑PEG͒ onto the particles is used to reduce the surface charge effect. 19 For comparison we have performed a study of the biodistribution of ferrite radiobeads conjugated with PEG. As shown in Fig. 3 , the normalized radio-density of the uptake by heart increases rapidly in the first 10 s and sequentially decreases in an approximately inverse exponential function of time. The specifics of the initial uptake are obviously different from those of ferrite beads without the PEG overlayer.
This result is in accord with the appearance of the scintigraphic images. The right insets in Fig. 3 display the scintigraphic images taken at 5 min after intravenous injection of radiobeads with PEG overlayer. For radiobeads conjugated with PEG, most of the injected beads escape from the uptake by liver and reach a nearly even concentration in the body. On the other hand, most of the injected radiobeads without the PEG modification are taken up by the liver and lung. This result manifests the alteration of the pharmacokinetic behavior by surface charge modification with PEG.
In conclusion, a novel process is developed to prepare directly labeled Tc-99m ferrite beads, which serve as a tracer to monitor the time varying particle uptake by organs. The pharmacokinetic behavior of intravenously injected radiobeads is ascribed to the absorption and excretion process of particles among the heart, lung, and liver and can be qualitatively described by a two-compartmental model. The characteristic features of particle uptake by organs can be altered by PEG modification of the particles. Further analysis of the quantitative parameters of nanoparticle pharmacokinetics is of interest to biomedical applications. 
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